QSP modeling to optimize drug development
InSysBio (insysbio.com) scores 74 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, SaaS brands, Technology brands, in the 39th percentile of 16259 Healthcare brands.
InSysBio is a Moscow-based company founded in 2004 that specializes in Quantitative Systems Pharmacology (QSP) and mechanistic PK/PD and PK/RO modeling of antibodies. It provides modeling solutions to pharmaceutical and biotech companies to predict drug efficacy in humans from animal data and optimize combinational therapies. The company positions itself as a specialized QSP provider, helping drug developers make data-driven decisions throughout the drug development process, aiming to accelerate and de-risk therapeutic development for global pharmaceutical partners.
| Brand Name | InSysBio |
|---|---|
| Domain | insysbio.com |
| Industry | Healthcare, SaaS |
| Founded | 2004 |
| Headquarters | Moscow |
| Main Competitors | Certara (87/100), Applied BioMath (81/100), Rosa & Co (74/100), Metrum Research Group (74/100), Simulations Plus (68/100) |
Moz Domain Authority 20/100 vs category average 40 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "InSysBio provides Quantitative Systems Pharmacology and Mechanistic PK/PD and PK/RO modeling of antibodies to optimize drug development" (Meta description: 17 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Apache.
Social footprint: verified profiles on LinkedIn, X (Twitter), YouTube, Instagram, GitHub; no detected presence on Facebook - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is InSysBio?", Claude could identify the brand as of October 2026. InSysBio is a biotech company specializing in quantitative systems pharmacology (QSP) and mechanistic mathematical modeling, providing modeling and simulation services to pharmaceutical and biotech companies to support drug development and decision-making. Best known for Quantitative systems pharmacology (QSP) modeling services for drug development.
When asked "Best brands similar to InSysBio?", Claude would recommend InSysBio as of October 2026. It's a known niche player in QSP/systems biology modeling for pharma, so it would be relevant to mention alongside other modeling and simulation consultancies in healthcare.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
InSysBio's main competitors in Healthcare: Certara (87/100), Applied BioMath (81/100), Rosa & Co (74/100), Metrum Research Group (74/100), Simulations Plus (68/100).
Sources: Brand Analyzer scan
InSysBio has limited AI-search visibility, scoring 27/100 on Brand Analyzer's AI visibility composite (visibility 21, trust 22, recommendation 45). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: InSysBio official site
InSysBio was founded in 2004. InSysBio operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
InSysBio is headquartered in Moscow. InSysBio operates in the Healthcare category.
Sources: Wikidata
InSysBio offers Quantitative Systems Pharmacology (QSP) modeling services, along with mechanistic PK/PD and PK/RO modeling specifically for antibody-based therapeutics. These services are designed to predict drug efficacy in humans using animal data and to optimize the design of combinational drug therapies.
Sources: InSysBio official site
InSysBio scores 45/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: InSysBio official site
InSysBio is a specialized Quantitative Systems Pharmacology (QSP) company based in Moscow, Russia, founded in 2004. It focuses on mechanistic PK/PD and PK/RO modeling of antibodies to support pharmaceutical drug development.
Sources: InSysBio official site
InSysBio develops and applies Quantitative Systems Pharmacology and mechanistic PK/PD and PK/RO modeling to predict drug efficacy in humans based on animal data and to optimize combinational therapies. These modeling services help pharmaceutical and biotech companies make informed, data-driven decisions during drug development, aiming to accelerate timelines and reduce development risk.
Sources: InSysBio official site
InSysBio can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: InSysBio official site
InSysBio's services are used by pharmaceutical and biotech companies, drug developers, and research scientists who require quantitative modeling expertise to optimize drug efficacy predictions and development strategies.
Sources: InSysBio official site
InSysBio is known for its expertise in Quantitative Systems Pharmacology (QSP) and mechanistic modeling of antibody pharmacokinetics and pharmacodynamics (PK/PD) and receptor occupancy (PK/RO), used to support drug development decisions for pharmaceutical partners.
Sources: InSysBio official site
InSysBio scores 27/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
InSysBio has a weak AI-visibility profile at 27/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (45/100) and its weakest is visibility (21/100). It benefits from a Wikidata knowledge-graph entry and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, a low Moz Domain Authority of 20/100 and thin schema.org structured data. In a live check, Claude could already identify InSysBio from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to InSysBio: Instinct Science (74/100), Inspirata (74/100), Integer (74/100), IntelliCred (74/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.